Skip to main content
Erschienen in: Annals of Hematology 5/2021

23.03.2021 | Original Article

Opioids are not a major cause of death of patients with sickle cell disease

verfasst von: Samir K. Ballas

Erschienen in: Annals of Hematology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

According to the Center of Disease Control and Prevention (CDC) database, the total number of deaths due to opioid overdose from 1999 through 2018 was 840,629. Given the alarming nature of these statistics, patients who requested prescription for opioids became targets of suspicion and possible accusation of maladaptive behavior. Patients with sickle cell disease (SCD) were often not exempt from such accusations and became guilty by association. In order to clarify the effect of opioids on the mortality of patients with SCD, the mortality rates for children and adults with SCD were investigated using the CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) Multiple Cause of Death database which is based on all the death certificates issued in the USA from 1999 to 2018. The data showed that 15,765 patients with SCD died from 1999 to 2018. Only 348 patients with SCD died due to opioids. The CDC database contains 27 categories of death based on ICD-10 codes in patients with SCD, and opioids were the 19th ranking cause of death. Surprisingly the most common causes of death of patients with SCD included circulatory, infection, respiratory, genitourinary, and vaso-occlusive crises/acute chest syndrome disorders in decreasing frequency. The mean age of death of females was 41.9 years and of males 39.3 years (p < 0.0001). Death due to SCD and death due to SCD and opioids were highest in the Southern Region of the USA.
Literatur
1.
Zurück zum Zitat Ballas SK (1994) Neurobiology and treatment of pain. In: Embury SH, Hebble RP, Mohandas N, et al., editors. Sickle cell disease: basic principles and clinical practice. New York: Raven Press:745–772 Ballas SK (1994) Neurobiology and treatment of pain. In: Embury SH, Hebble RP, Mohandas N, et al., editors. Sickle cell disease: basic principles and clinical practice. New York: Raven Press:745–772
2.
Zurück zum Zitat Ballas SK (1993) Management of sickle cell disease. Hosp Physician 29:12–15 29–35 Ballas SK (1993) Management of sickle cell disease. Hosp Physician 29:12–15 29–35
3.
Zurück zum Zitat Ballas SK (1995) Sickle cell disease. In: Rakel R (ed) Conn's current therapy. WB Saunders, Philadelphia, pp 318–327 Ballas SK (1995) Sickle cell disease. In: Rakel R (ed) Conn's current therapy. WB Saunders, Philadelphia, pp 318–327
4.
Zurück zum Zitat Benjamin L (1989) Pain in sickle cell disease. In: Foley K, Payne R (eds) Current therapy of pain. BC Decker, Toronto, pp 90–104 Benjamin L (1989) Pain in sickle cell disease. In: Foley K, Payne R (eds) Current therapy of pain. BC Decker, Toronto, pp 90–104
5.
Zurück zum Zitat Payne R (1989) Pain management in sickle cell disease. Rationale and techniques. Ann N Y Acad Sci 565:189–206CrossRef Payne R (1989) Pain management in sickle cell disease. Rationale and techniques. Ann N Y Acad Sci 565:189–206CrossRef
6.
Zurück zum Zitat Ballas SK (2014) Sickle cell pain, 2nd Edition. Washington DC: International Association for the Study of Pain Ballas SK (2014) Sickle cell pain, 2nd Edition. Washington DC: International Association for the Study of Pain
7.
Zurück zum Zitat Pentin PL (2013) Drug seeking or pain crisis? Responsible prescribing of opioids in the emergency department. Virtual Mentor 15:410–415PubMed Pentin PL (2013) Drug seeking or pain crisis? Responsible prescribing of opioids in the emergency department. Virtual Mentor 15:410–415PubMed
8.
Zurück zum Zitat Abrams DI, Couey P, Dixit N, Sagi V, Hagar W, Vichinsky E, Kelly ME, Connett JE, Gupta K (2020) Effect of inhaled cannabis for pain in adults with sickle cell disease: a randomized clinical trial. JAMA Netw Open 3:e2010874CrossRef Abrams DI, Couey P, Dixit N, Sagi V, Hagar W, Vichinsky E, Kelly ME, Connett JE, Gupta K (2020) Effect of inhaled cannabis for pain in adults with sickle cell disease: a randomized clinical trial. JAMA Netw Open 3:e2010874CrossRef
9.
Zurück zum Zitat White CM (2019) Pharmacologic and clinical assessment of kratom: an update. Am J Health Syst Pharm 76:1915–1925CrossRef White CM (2019) Pharmacologic and clinical assessment of kratom: an update. Am J Health Syst Pharm 76:1915–1925CrossRef
10.
Zurück zum Zitat Ruta NS, Ballas SK (2016) The opioid drug epidemic and sickle cell disease: guilt by association. Pain Med 17:1793–1798CrossRef Ruta NS, Ballas SK (2016) The opioid drug epidemic and sickle cell disease: guilt by association. Pain Med 17:1793–1798CrossRef
11.
Zurück zum Zitat Ballas SK, Kanter J, Agodoa I, Howard R, Wade S, Noxon V, Dampier C (2018) Opioid utilization patterns in United States individuals with sickle cell disease. Am J Hematol 93:E345–e347CrossRef Ballas SK, Kanter J, Agodoa I, Howard R, Wade S, Noxon V, Dampier C (2018) Opioid utilization patterns in United States individuals with sickle cell disease. Am J Hematol 93:E345–e347CrossRef
12.
Zurück zum Zitat Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G (2018) Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep 67:1419–1427CrossRef Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G (2018) Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep 67:1419–1427CrossRef
13.
Zurück zum Zitat Wilson N, Kariisa M, Seth P, Smith H IV, Davis NL (2020) Drug and opioid-involved overdose deaths - United States, 2017-2018. MMWR Morb Mortal Wkly Rep 69:290–297CrossRef Wilson N, Kariisa M, Seth P, Smith H IV, Davis NL (2020) Drug and opioid-involved overdose deaths - United States, 2017-2018. MMWR Morb Mortal Wkly Rep 69:290–297CrossRef
14.
Zurück zum Zitat Centers for Disease Control and Prevention. CDC WONDER Multiple Cause of Death database, 1999-2018. 2020. Centers for Disease Control and Prevention. CDC WONDER Multiple Cause of Death database, 1999-2018. 2020.
15.
Zurück zum Zitat Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639–1644CrossRef Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639–1644CrossRef
16.
Zurück zum Zitat Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J Jr, Shah AK, Mankad VN, Investigators of the Cooperative Study of Sickle Cell Disease (2003) Causes of death in sickle cell disease: an autopsy study. Br J Haematol 123:359–365CrossRef Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J Jr, Shah AK, Mankad VN, Investigators of the Cooperative Study of Sickle Cell Disease (2003) Causes of death in sickle cell disease: an autopsy study. Br J Haematol 123:359–365CrossRef
17.
Zurück zum Zitat Darbari DS, Wang Z, Kwak M, Hildesheim M, Nichols J, Allen D, Seamon C, Peters-Lawrence M, Conrey A, Hall MK, Kato GJ, Taylor VI JG (2013) Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. PLoS One 8:e79923CrossRef Darbari DS, Wang Z, Kwak M, Hildesheim M, Nichols J, Allen D, Seamon C, Peters-Lawrence M, Conrey A, Hall MK, Kato GJ, Taylor VI JG (2013) Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. PLoS One 8:e79923CrossRef
18.
Zurück zum Zitat Elmariah H, Garrett ME, De Castro LM et al (2014) Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol 89:530–535CrossRef Elmariah H, Garrett ME, De Castro LM et al (2014) Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol 89:530–535CrossRef
19.
Zurück zum Zitat Lanzkron S, Carroll CP, Haywood C Jr (2013) Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep 128:110–116CrossRef Lanzkron S, Carroll CP, Haywood C Jr (2013) Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep 128:110–116CrossRef
20.
Zurück zum Zitat Lubeck D, Agodoa I, Bhakta N, Danese M, Pappu K, Howard R, Gleeson M, Halperin M, Lanzkron S (2019) Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw Open 2:e1915374CrossRef Lubeck D, Agodoa I, Bhakta N, Danese M, Pappu K, Howard R, Gleeson M, Halperin M, Lanzkron S (2019) Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw Open 2:e1915374CrossRef
21.
Zurück zum Zitat Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J (2014) Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 312:1033–1048CrossRef Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J (2014) Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 312:1033–1048CrossRef
22.
Zurück zum Zitat Expert Panel Report. Evidence-Based Management of Sickle Cell Disease. In: U.S. Department of Health and Human Services editor. Bethesda MD: National Heart, Lung, and Blood Institute; 2014. Expert Panel Report. Evidence-Based Management of Sickle Cell Disease. In: U.S. Department of Health and Human Services editor. Bethesda MD: National Heart, Lung, and Blood Institute; 2014.
23.
Zurück zum Zitat Lobo CLC, Nascimento EMD, Jesus LJC, Freitas TG, Lugon JR, Ballas SK (2018) Mortality in children, adolescents and adults with sickle cell anemia in Rio de Janeiro, Brazil. Rev Bras Hematol Hemoter 40:37–42PubMed Lobo CLC, Nascimento EMD, Jesus LJC, Freitas TG, Lugon JR, Ballas SK (2018) Mortality in children, adolescents and adults with sickle cell anemia in Rio de Janeiro, Brazil. Rev Bras Hematol Hemoter 40:37–42PubMed
24.
Zurück zum Zitat Santo AH (2020) Sickle cell disease related mortality in Brazil, 2000-2018. Hematol Transfus Cell Ther Santo AH (2020) Sickle cell disease related mortality in Brazil, 2000-2018. Hematol Transfus Cell Ther
Metadaten
Titel
Opioids are not a major cause of death of patients with sickle cell disease
verfasst von
Samir K. Ballas
Publikationsdatum
23.03.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 5/2021
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-021-04502-2

Weitere Artikel der Ausgabe 5/2021

Annals of Hematology 5/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.